These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22470169)

  • 1. Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study.
    Etminan M; Forooghian F; Maberley D
    CMAJ; 2012 May; 184(8):E431-4. PubMed ID: 22470169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort.
    French DD; Margo CE
    Retina; 2008 Jun; 28(6):889-93. PubMed ID: 18536608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates: uveitis and scleritis.
    Prescrire Int; 2013 May; 22(138):128. PubMed ID: 23819179
    [No Abstract]   [Full Text] [Related]  

  • 4. Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort.
    Fraunfelder FW; Winthrop K; Suhler E; Choi D; Fraunfelder FT
    Retina; 2009 Feb; 29(2):285-6; author reply 286-7. PubMed ID: 19202428
    [No Abstract]   [Full Text] [Related]  

  • 5. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort.
    Kim SY; Schneeweiss S; Katz JN; Levin R; Solomon DH
    J Bone Miner Res; 2011 May; 26(5):993-1001. PubMed ID: 21542002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular Side Effects of Bisphosphonates: A Review of Literature.
    Chartrand NA; Lau CK; Parsons MT; Handlon JJ; Ronquillo YC; Hoopes PC; Moshirfar M
    J Ocul Pharmacol Ther; 2023; 39(1):3-16. PubMed ID: 36409537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scleritis and Intraorbital Inflammation following Oral and Intravenous Bisphosphonates in a 66-Year-Old Man.
    Heck K; Malinina S; Palmowski A
    Klin Monbl Augenheilkd; 2024 Apr; 241(4):426-428. PubMed ID: 38653272
    [No Abstract]   [Full Text] [Related]  

  • 8. Aminobisphosphonate-associated orbital and ocular inflammatory disease.
    Keren S; Leibovitch I; Ben Cnaan R; Neudorfer M; Fogel O; Greenman Y; Shulman S; Zur D; Habot-Wilner Z
    Acta Ophthalmol; 2019 Aug; 97(5):e792-e799. PubMed ID: 30816018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bisphosphonate-induced ocular and orbital inflammation].
    Jakobsen TS; Funding M
    Ugeskr Laeger; 2022 Jul; 184(28):. PubMed ID: 35959811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral Bisphosphonate use Reduces Cardiovascular Events in a Cohort of Danish Patients Referred for Bone Mineral Density.
    Rodríguez AJ; Ernst MT; Nybo M; Prieto-Alhambra D; Ebeling PR; Hermann AP; Abrahamsen B
    J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32717068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral bisphosphonate use and age-related macular degeneration: retrospective cohort and nested case-control study.
    Garriga C; Pazianas M; Hawley S; Delmestri A; Prieto-Alhambra D; Cooper C; Judge A
    Ann N Y Acad Sci; 2018 Mar; 1415(1):34-46. PubMed ID: 29363763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular side effects associated with bisphosphonates.
    Fraunfelder FW
    Drugs Today (Barc); 2003 Nov; 39(11):829-35. PubMed ID: 14702129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exposure to oral bisphosphonates and risk of esophageal cancer.
    Cardwell CR; Abnet CC; Cantwell MM; Murray LJ
    JAMA; 2010 Aug; 304(6):657-63. PubMed ID: 20699457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of oral bisphosphonates and risk of venous thromboembolism: a population-based case-control study.
    Lamberg AL; Horvath-Puho E; Christensen S; Sørensen HT
    Osteoporos Int; 2010 Nov; 21(11):1911-7. PubMed ID: 19997902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial.
    Patel DV; Bolland M; Nisa Z; Al-Abuwsi F; Singh M; Horne A; Reid IR; McGhee CN
    Osteoporos Int; 2015 Feb; 26(2):499-503. PubMed ID: 25187119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteonecrosis of the jaw in older osteoporosis patients treated with intravenous bisphosphonates.
    Baillargeon J; Kuo YF; Lin YL; Wilkinson GS; Goodwin JS
    Ann Pharmacother; 2011 Oct; 45(10):1199-206. PubMed ID: 21954448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study.
    Etminan M; Aminzadeh K; Matthew IR; Brophy JM
    J Rheumatol; 2008 Apr; 35(4):691-5. PubMed ID: 18203310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonate use and gastrointestinal tract cancer risk: meta-analysis of observational studies.
    Oh YH; Yoon C; Park SM
    World J Gastroenterol; 2012 Oct; 18(40):5779-88. PubMed ID: 23155320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates for Paget's disease of bone in adults.
    Corral-Gudino L; Tan AJ; Del Pino-Montes J; Ralston SH
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD004956. PubMed ID: 29192423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.